For patients with high-risk, operable breast cancer requiring PMRT with IMNI, the 16-fraction HypoRT regimen is noninferior to ConvRT for locoregional control, offers a superior acute toxicity profile, and demonstrates excellent cardiopulmonary safety.
Xiao-Fang Wang, Xiao-Meng Zhang, Xing-Xing Chen et al.· Journal of Clinical Oncology· 0 citations
The findings identify the ESAM/Calnexin/mTOR axis as a candidate biomarker and therapeutic vulnerability in HER2-positive breast cancer and attenuates sensitivity to anti-HER2 therapy.
Xiao-Ting Chen, Xu-Jie Zhou, Y. Sang et al.· Cell Death Discovery· 0 citations
Objective
Age-associated molecular heterogeneity is well described in female breast cancer but remains insufficiently characterized in male breast cancer (MBC). We profiled age-stratified clinical and molecular differences between younger (≤55 years) male breast cancer (YMBC) and older (>55 years) male breast cancer (O...
Zhi-Shuang Gao, Ze-Hao Wang, Yue Zhou et al.· Chinese journal of cancer re...· 0 citations
The results found that women diagnosed with FBC had an early onset of disease in the population studied, and the poor outcome of patients with a family history of BOC associated with survival was restricted to the hormone receptor-positive population.
The results of the present study suggest that ML can inhibit the proliferation and migration of BRCA cells whilst inducing their apoptosis by regulating the expression of key proteins.
Jun Zhang, Guo-Xin Zhao, Renping Zhang et al.· American Journal of Cancer R...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
